Neurobehavioral Substrates of Propranolol's Effects on Drug Cue Reactivity
Status:
Completed
Trial end date:
2019-07-15
Target enrollment:
Participant gender:
Summary
The central objective of this project is to obtain proof-of-concept data demonstrating the
effects of propranolol (a beta-adrenergic antagonist) on neurobiological responses to
personal smoking environments and behavioral responses in a laboratory smoking behavior task.
Human cigarette smokers (N = 50) will take photographs of locations where they do and do not
smoke cigarettes. They will then be randomly assigned to receive either propranolol (40 mg)
or placebo prior to completing: A) An MRI session assessing neural responses to personal
smoking/non-smoking environments, standard smoking/non-smoking environments and proximal
smoking/non-smoking cues; and B) A laboratory session examining smoking behavior in response
to environmental cues.
Phase:
Phase 4
Details
Lead Sponsor:
Duke University
Collaborators:
National Institute on Drug Abuse (NIDA) National Institutes of Health (NIH)